Background {#Sec1}
==========

The tonsils, a subsite of the oropharynx, are the most common site of oropharyngeal neoplasm \[[@CR1]\]. The incidence of tonsil cancer is increasing \[[@CR2], [@CR3]\]. Odynophagia, dysphagia, otalgia and asymptomatic mass is common presentations. Histologically, squamous cell carcinoma is most commonly observed in tonsil cancer. Regional nodal metastases are frequent in more than half of patients, while contralateral nodal diseases are found in more than one fifth of patients with tonsil cancer \[[@CR4]\]. Management of tonsil cancer is limited to either surgery or radiotherapy, yet there is a scarcity of randomized prospective trials comparing these treatment options. However, several retrospective studies published similar oncologic outcomes with both modalities \[[@CR5]--[@CR7]\]. Therefore, current guidelines recommend both strategies based on such findings \[[@CR8]\].

In recent decades, breakthroughs in the field have included the introduction of chemotherapy, resulting in improved survival rates after definitive radiotherapy and postoperative radiotherapy \[[@CR9], [@CR10]\]. Furthermore, randomized clinical trial data showed that more than half of oropharyngeal cancers were human papillomavirus (HPV) positive and responded well to definitive radiotherapy \[[@CR11]\]. The incidence of HPV positive tumors is continuously increasing \[[@CR12]\]. In the era of chemotherapy and endemic HPV, comparisons of the efficacy between treatment modalities is still controversial. In the present study, we conducted a large-scale retrospective multicenter study to evaluate the outcome of chemoradiotherapy and surgery followed by postoperative radiotherapy in tonsil cancer patients.

Methods {#Sec2}
=======

A total of 620 tonsil cancer patients who were treated with radiotherapy between 1998 and 2010 were identified in 16 institutions in Korea. Of these, we analyzed data from 586 patients who were treated with definitive radiotherapy with chemotherapy (CRT; 201 patients) or surgery followed by radiotherapy and/or chemotherapy (SRT; 385 patients). All institutional review boards of participating hospitals approved the collection of these data. The need for consent had been waived by the institutional review boards. Patient demographics, performance status, smoking history, imaging study, stage, pathology, type of surgery, radio- and chemotherapeutic information, and follow-up results were compiled.

The median age at diagnosis was 56 (range, 26--89) and patients were predominantly male (89%). The performance status of most patients was Eastern Cooperative Oncology Group (ECOG) grade 0--1 (94%). More than half of the patients (52%) had a history of smoking. Computed tomography (CT) scans of the neck were performed at diagnosis in 91% of individuals; positron emission tomography (PET) or CT scans were taken in 69% of patients, while magnetic resonance imaging of the oropharynx and neck was performed in 48%.

Patient characteristics according to the two treatment groups are summarized in Table [1](#Tab1){ref-type="table"}. Younger patients and those with early T stage were more likely to receive surgery (*p* = 0.041 and 0.002, respectively). Unknown histologic differentiation was less frequent in the SRT group. Chemotherapy and intensity modulated radiotherapy (IMRT) were more commonly used in the CRT group (*p* \< 0.001 and 0.014, respectively). Radiotherapy dose was also higher in the CRT group than in those receiving SRT (*p* \< 0.001).Table 1Patient CharacteristicsCharacteristicNumber of patients (%)All (*n* = 586)CRT (*n* = 201)SRT (*n* = 385)*p*-valueSex0.913 Male523(89)179(89)344(89) Female63(11)22(11)41(11)Age (years)0.041 \< 60395(67)125(62)270(70) ≥ 60189(32)76(38)113(29) Unknown2(0)0(0)2(1)Smoker0.673 Never smoker232(40)73(36)159(41) Ex-smoker ^a^98(17)32(16)66(17) Current smoker206(35)73(36)133(35) Unknown50(8)23(11)27(7)Performance0.351 ECOG 0197(34)74(37)123(32) ECOG 1351(60)117(58)234(61) ECOG 221(3)5(2)16(4) Unknown17(3)5(2)12(3)PET/CT0.072 No182(31)72(36)110(29) Yes404(69)129(64)275(71)Differentiation\<0.001 WD62(11)15(7)47(12) MD297(51)73(36)224(58) PD129(22)37(18)92(24) UD16(3)11(5)5(1) Unknown82(14)65(32)17(4)T stage0.002 T1134(23)31(15)103(27) T2292(50)101(50)191(50) T374(13)30(15)44(11) T4a73(12)30(15)43(11) T4b13(2)9(4)4(1)N stage0.779 N073(12)20(10)53(14) N179(13)28(14)51(13) N2a45(8)16(8)29(8) N2b307(52)105(52)202(52) N2c60(10)23(11)37(10) N322(4)9(4)13(3)Stage0.092 I8(1)2(1)6(2) II42(7)23(11)37(10) III82(14)29(14)53(14) IVA419(72)143(71)276(72) IVB35(6)18(9)17(4)Chemotherapy\<0.001 Induction61(10)33(16)28(7) Concurrent244(42)167(83)77(20) Adjuvant13(2)1(1)12(3) No268(46)0(0)268(70)Radiotherapy technique0.014 3D--CRT391(67)121(60)270(70) IMRT194(33)80(40)114(30) Unknown1(0)0(0)1(0)Total dose of radiotherapyMedian 66Median 70Median 63\<0.001 (Gy)(range, 25.2--76)(range, 59.4--76)(range, 25.2--72.6)*Abbreviations: CRT* radiotherapy with chemotherapy, *SRT* surgery followed by radiotherapy, *ECOG* Eastern Cooperative Oncology Group, *PET/CT* positron emission tomography/computed tomography, *WD* well differentiated, *MD* moderate differentiation, *PD* poor differentiation, *UD* undifferentiated, *3D--CRT* three-dimensional conformal radiotherapy, *IMRT* intensity modulated radiotherapy^a^An adult who has smoked at least 100 cigarettes in his or her lifetime but who had quit smoking at the time of diagnosis

Overall survival (OS) was defined as the time from the date of treatment initiation to either death or last follow-up. Disease-free survival (DFS) was defined as the time from treatment initiation to recurrence, death, or last follow-up. Locoregional recurrence-free survival (LRRFS) and distant metastasis-free survival (DMFS) were defined as the time from treatment initiation to locoregional/distant recurrence or last follow-up, respectively. Univariate and multivariate analyses were performed using the log rank test and Cox-proportional hazard regression model, respectively.

Results {#Sec3}
=======

With a median follow-up duration of 54 months (range, 2--176 months), 67 (11%) patients demonstrated locoregional recurrence, while 50 (9%) patients failed with distant metastases. The 5-year OS, DFS, LRRFS, and DMFS rates of the cohort as a whole were 81, 75, 87, and 91%, respectively. When the data from the CRT and SRT groups were analyzed independently, no significant differences were observed between the two groups. The 5-year OS rates were 82 and 81% (*p* = 0.698) in the CRT and SRT groups, respectively; DFS, 78 and 73% (*p* = 0.612); LRRFS, 89 and 87% (*p* = 0.695); and DMFS, 94 and 89% (*p* = 0.157). The survival curves of each group are plotted in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Overall survival, disease-free survival, locoregional recurrence-free survival, and distant metastasis-free survival according to treatment group

Older age, current smoking, advanced T and N stage, and induction chemotherapy treatment were associated with poor OS in the univariate analysis (Table [2](#Tab2){ref-type="table"}). Furthermore, patients undergoing induction chemotherapy showed inferior survival in both treatment groups (Fig. [2](#Fig2){ref-type="fig"}); the 5-year OS rates of patients treated with and without induction chemotherapy were 71 and 83%, respectively (*p* \< 0.001). This significant finding was also observed when the treatment groups were analyzed independently; in the CRT group, the 5-year OS rates of patients with or without induction chemotherapy were 70 and 84% (*p* = 0.001), respectively, and 72% vs 82% in the SRT group (*p* = 0.033).Table 2Univariate AnalysesCharacteristicOSDFSLRRFSDMFSNo.5Y (%)*p*-valueNo.5Y (%)*p*-valueNo.5Y (%)*p*-valueNo.5Y (%)*p*-valueSex Male523800.082521730.037525860.025522910.787 Female6390638863946391Age (years) \< 6039585\<0.00139380\<0.001395890.121394920.026 ≥ 6018973189621898318986Smoking history Never/ex-smoker330850.001329790.001330900.005330920.306 Current smoker20676205672068220589Performance status ECOG 0197850.094197800.027197930.008197920.45 ECOG 1--237279370723728537190PET/CT No182790.226181740.847182880.669182930.311 Yes40483403744048740389T stage T1--T242687\<0.00142581\<0.001426900.00342594\<0.001 T3--T416067159581608116082N stage N0--N2b504840.00550378\<0.001504880.05550483\<0.001 N2c--N38267815582818179Stage I--III132900.066132850.016132930.06132970.004 IVA--IVB45479452724548645389Chemotherapy Concurrent/no52583\<0.001523760.006525880.263524900.762 Induction6171616461836193Radiotherapy technique 3D--CRT391800.420389740.36391870.754390900.235 IMRT19484194761948819492Treatment modality CRT201820.698201780.612201890.695201940.157 SRT38581383733858738489*Abbreviations: OS* overall survival, *DFS* disease-free survival, *LRRFS* locoregional recurrence-free survival, *DMFS* distant metastasis-free survival, *ECOG* Eastern Cooperative Oncology Group, *PET/CT* positron emission tomography--computed tomography, *3D--CRT* three-dimensional conformal radiotherapy, *IMRT* intensity modulated radiotherapy, *CRT* radiotherapy with chemotherapy, *SRT* surgery followed by radiotherapy Fig. 2Overall survival according to presence or absence of induction chemotherapy in each treatment group

The multivariate analysis (Table [3](#Tab3){ref-type="table"}) also indicated that induction chemotherapy was a risk factor for poor OS and DFS, but not for LRRFS or DMFS. Other prognostic factors such as old age, current smoking, poor initial performance status and advanced T stage were associated with inferior OS. For DFS, advanced N stage was an additional significant prognostic factor. However, in terms of LRRFS, patient age and use of induction chemotherapy were not included in the Cox model. Age, and T and N stage were also identified as independent prognostic factors for DMFS.Table 3Multivariate AnalysesOSDFSLRRFSDMFSCharacteristics*p*-valueHR95% CI*p*-valueHR95% CI*p*-valueHR95% CI*p*-valueHR95% CIAge (years) ≥ 60\<0.0013.0002.001--4.497\<0.0012.5161.779--3.5600.0092.2271.217--4.077Smoking history Current smoker0.0121.6631.116--2.4780.0151.541.089--2.1760.0141.9191.141--3.226Performance status ECOG 1--20.0451.5661.010--2.4260.0171.5871.087--2.3150.0192.0941.130--3.879T stage T3--T4\<0.0012.9131.943--4.366\<0.0012.5721.808--3.6590.0211.8521.097--3.127\<0.0013.3121.804--6.082N stage N2c--N30.0691.5420.966--2.4620.0081.7351.155--2.6070.0751.7470.946--3.2260.0072.4351.271--4.664Chemotherapy Induction0.0032.2241.313--3.7680.0331.7121.044--2.806*Abbreviations: OS* overall survival, *DFS* disease-free survival, *LRRFS* locoregional recurrence-free survival, *DMFS* distant metastasis-free survival, *HR* hazard ratio, *CI* confidence interval, *ECOG* Eastern Cooperative Oncology Group

Discussion {#Sec4}
==========

Controversy surrounds the treatment of tonsil cancer. Both definitive surgery and radiotherapy resulted in favorable outcomes in retrospective studies \[[@CR5]--[@CR7]\]. With the use of chemotherapy, improved survival rates were reported with both treatment modalities \[[@CR9], [@CR10]\]. However, no well-designed prospective study comparing radiotherapy and surgery has been completed in the era of widely used chemotherapy. The only prospective randomized trial comparing chemoradiotherapy and surgery followed by radiotherapy was stopped prematurely due to slow accrual and therefore failed to detect any significant difference in DFS between treatment groups \[[@CR13]\].

In the present study, we report the outcome of 586 patients from 16 hospitals. To the best of our knowledge, this is one of the largest tonsil cancer cohorts in the literature. We found that old age and advanced T stage which were associated with inferior survival in a multivariate analysis are more found in the CRT group. Despite these discrepancies in patient demographic and disease stage, there was no significant difference between the two treatment modalities under investigation in terms of survival, recurrence, or failure pattern. Our findings suggest that the CRT approach is more effective than SRT; however, further studies are required to confirm this hypothesis.

If the outcome is comparable between two treatment options, morbidity associated with the treatment becomes important when choosing the treatment modality. Unfortunately, we were unable to collect extensive information regarding treatment-related toxicities. Future trials should address not only the outcomes of treatment, but also any associated complications.

The outcomes of our multicenter study are comparable with those of previously published series. Canis et al. reported the outcome of 102 tonsil cancer patients who were treated with transoral laser microsurgery \[[@CR14]\]. The 5-year locoregional control rates of T1--T2 and T3--T4 stage tumors were 78 and 75%, respectively. In the current study, the corresponding rates were 90 and 81%, respectively. Similarly, researchers from MD Anderson Cancer Center reported 5-year locoregional control and OS rates of 97 and 86%, respectively, in 120 patients who were treated with tonsillectomy followed by postoperative radiotherapy \[[@CR15]\]. Poulsen et al. studied the outcomes of 148 patients who received surgery followed by radiotherapy or definitive radiotherapy \[[@CR16]\], yielding 5-year locoregional control and OS rates of 84 and 57%, respectively. Other studies performed before the early 2000s reported lower 5-year locoregional control rates of 63--77% and OS rates of 53--60% \[[@CR7], [@CR17]--[@CR19]\], possibly because these studies included a large proportion of patients who were treated in the pre-chemotherapy era. Although direct comparisons are not possible, our treatment outcomes are acceptable when compared with the literature.

In the present study, the induction chemotherapy approach negatively influenced both OS and DFS, but had little effect on LRRFS or DMFS in the multivariate analysis. These findings suggest that induction chemotherapy may cause non-cancer related death. Recently, randomized trials reported increased toxicities and no survival gain with induction chemotherapy \[[@CR20], [@CR21]\]. Despite the limitations of retrospective studies (e.g., patient selection), our findings support the proposal that the toxicity associated with routine use of induction chemotherapy might be potentially harmful to tonsil cancer patients who are highly curable without such treatment. This is further indicated by our finding that patients with tonsil cancer showed favorable prognosis and a low rate of distant metastasis, despite 86% demonstrating stage III--IVA disease.

Tobacco smoking is a well-known risk factor for head and neck cancer \[[@CR22]\]. Indian researchers reported that prior tobacco abuse was an independent poor prognostic factor for DFS and locoregional control in oropharyngeal cancer \[[@CR23]\]. Less than half of tumors in that study were located in the tonsils. In our study, current smokers showed significantly worse OS, DFS, and LRRFS than non- or ex-smokers in the multivariate analysis. Differing tumor biology in smokers may affect disease outcome \[[@CR24]\]. It is well known that persistent smoking during radiation therapy adversely affects the response and survival rate of head and neck cancer patients \[[@CR25]\]. Smoking cessation may be beneficial and should be encouraged in patients with tonsil cancer.

Age of \>60 years was associated with a significant risk of death, disease recurrence, and distant metastasis in the multivariate analysis. HPV infection, which correlated with favorable prognosis, was more frequently observed in younger patients than in the elderly; \[[@CR12]\] therefore, smoking history and old age could be secondary surrogates of poor tumor biology which is unrelated to HPV infection. Unfortunately, because the HPV status of patients in the present study was unknown, this hypothesis could not be tested. Regarding that many recent studies for altering therapy based on HPV status are in progress, the lack of details of HPV status in this study has significant limitations \[[@CR26]\].

Conclusion {#Sec5}
==========

Our large, multicenter, retrospective review of tonsil cancer patients showed favorable survival and disease control. Despite more high-risk patients being treated with definitive chemoradiotherapy than surgery followed by radiotherapy, demonstrated comparable outcomes. Furthermore, our study indicated that induction chemotherapy is correlated with significant risk of death and should not be routinely given to tonsil cancer patients.
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